Next Generation Psychedelics Drug Discovery

Jun 26, 2021

One positive outcome from the Covid-19 pandemic has been innovation in drug development practices and tools. Many highly successful (and fingers crossed very low risk) Covid-19 vaccines have launched in record time.

Not only has the pharma response to the pandemic delivered tremendous healthcare, social and economic outcomes, but it has also spawned new and technologically advanced ways to develop beneficial medicines quickly and potentially less expensively.

Eastra Health has been paying attention. We are taking advantage of pandemic-inspired best practices (specifically from the Pfizer and BioNtech collaboration) as well as transformative digital tools to guide how we develop our female-focused psychedelic drugs.

The following innovations inspire the design and execution of our operating model which also supercharges our research plan.

 

A patient-centered approach

We utilize a ‘Purpose-Driven’ research model to ensure that our research effort starts with patient, physician, and regulatory needs and requirements. This unique approach includes understanding the patient experience before kicking off scientific research, talking to multiple physician specialties on their clinical needs, and engaging with the FDA at the discovery research stage.

A patient-centered approach will improve the odds of developing the correct medicine for the right indication and the right population. Furthermore, it will minimize wasteful research spending and enhance the likelihood that our target compounds can be efficiently commercialized and successfully marketed.

 

Cutting edge digital tools

Eastra Health will leverage next-generation computational biology, Big Data analytics, and machine learning tools to accelerate drug development and reduce the likelihood of expensive failures. These new tools and methodologies will assist us in finding new synthetic molecular structures with specific properties and novel target indication identification, not to mention predicting clinical trial outcomes.

AI-powered drug development is already here. These technologies have helped numerous drug developers identify a novel target molecule for various diseases, validate target novel molecules and designate a preclinical candidate – all in less than 18 months.

The strategic benefits are compelling, including faster time to clinical trials, enhanced decision-making ability, and de-risking research spending.

 

Values-based Partnerships

Nothing illuminates the power of partnership than the winning Covid-19 vaccine collaboration between drug giant Pfizer, and biotech leader BioNTech. Both companies leveraged a common purpose, ethics, and business values, allowing them to work quickly, symbiotically, and with a high degree of trust.

In fact, for much of the development period, there was no formal contract between the parties. Instead, underpinning their shared values and mission was the employment of a basket of collaborative work practices, full project transparency, and fully shared project information.

We recognized early on that if we want to fulfill our mission of bringing improved healthcare solutions to billions of women suffering from under-addressed conditions like PMS and menopause, we need to do business in an entirely different way.

Keeping the patient in our research bull’s-eye, leveraging the latest digital tools to accelerate drug discovery, and working symbiotically with ethically-minded collaborators are some of the ways we are looking to disrupt psychedelics drug development.

Mitchell Osak
CCSO